Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not

Core Insights - The article discusses the background and achievements of Brendan, highlighting his academic and professional journey in the pharmaceutical and biotechnology sectors. Group 1: Academic Background - Brendan completed a Ph.D. at Stanford University in organic synthesis in 2009 [1] Group 2: Professional Experience - He worked for Merck, a major pharmaceutical company, from 2009 to 2013 [1] - Brendan has experience in biotech, including startups such as Theravance and Aspira, before joining Caltech [1] - He was the first employee and co-founder of 1200 Pharma, which spun out of Caltech and secured significant investment in the eight figures [1] Group 3: Investment Focus - Brendan remains an avid investor, concentrating on market trends, particularly in biotechnology stocks [1]